Details of the Drug Reposition

General Information of This Drug (ID: DMNER5S)

Drug Name
Bleomycin   DMNER5S
Synonyms
BLM; Blenoxane; Bleo; Bleocin; Bleogin; Bleomicin; Bleomicina; Bleomycine; Bleomycins; Bleomycinum; Bleomycin sulfate; Bleomycin a2; Pingyangmyvin A2; Zhengguangmycin A2; Zhengguangmycin A2 [Chinese]; Blenoxane (TN); Bleomicina [INN-Spanish]; Bleomycin A(2); Bleomycin A2 & Bleomycin B2; Bleomycin B(2); Bleomycine [INN-French]; Bleomycinum [INN-Latin]; NDC 0015-3010; N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide; N1-(3-(Dimethylsulfonio)propyl)bleomycinamide
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
4 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Testicular germ cell tumor DIS5RN24 N.A. Approved [1]
Penile cancer DISGVGNQ N.A. Approved [1]
Cervical cancer DISFSHPF 2C77.0 Approved [1]
Head and neck cancer DISBPSQZ 2D42 Approved [1]
------------------------------------------------------------------------------------
1 Discontinued in Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Diffuse large B-cell lymphoma DISSACK3 2A81 Discontinued in Phase 3 [2]
------------------------------------------------------------------------------------
2 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Non-hodgkin lymphoma DISS2Y8A 2B33.5 Discontinued in Phase 2 [3]
Squamous cell carcinoma DISQVIFL 2B60-2D01 Discontinued in Phase 2 [4]
------------------------------------------------------------------------------------
3 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Classic Hodgkin lymphoma DISV1LU6 N.A. Investigative [1]
Follicular lymphoma DISVEUR6 2A80 Investigative [1]
Hodgkin lymphoma DISX2OUL 2B30 Investigative [5]
------------------------------------------------------------------------------------

References

1 Bleomycin FDA Label
2 A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy
3 Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML
4 Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
5 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.